A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1095-1102

  Patnaik, Amita ^a   Haluska, Paul ^b   Tolcher, Anthony W ^a   Erlichman, Charles ^b   Papadopoulos, Kyriakos P ^a   Lensing, Janet L ^b   Beeram, Muralidhar ^a   Molina, Julian R ^b   Rasco, Drew W ^a   Arcos, Rebecca R ^a   Kelly, Claudia S ^c   Wijayawardana, Sameera R ^c   Zhang, Xuekui ^c   Stancato, Louis F ^c   Bell, Robert ^c   Shi, Peipei ^c   Kulanthaivel, Palaniappan ^c   Pitou, Celine ^c   Mulle, Lynette B ^d   Farrington, Daphne L ^c   Chan, Edward M ^c   Goetz, Matthew P ^b   more..

^a START ^*  (United States)

^b MAYO CLINIC   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOCHROME P450 3A4; CYTOKINE; MAPKAP K2 PROTEIN; MIDAZOLAM; RALIMETINIB; TAMOXIFEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; LY2228820; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLEEDING; BREAST METASTASIS; CANCER MORTALITY; CAUCASIAN; CONSTIPATION; CONVULSION; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; HISPANIC; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; SARCOMA; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TREMOR; VOMITING; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; METASTASIS; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASMS; PATHOLOGY; TUMOR MICROENVIRONMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMIDAZOLES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; TUMOR MICROENVIRONMENT;

EID: 84962283275     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1718     Document Type: Article

References (16)

1. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.
2. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31.
3. Tate CM, Blosser W, Wyss L, Evans G, Xue Q, Pan Y, et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem 2013;288:6743-53.
4. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-69.
5. Norman P. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. ExpertOpin Investig Drugs 2015;24:383-92.
6. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26.
7. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38 (MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369-79.
8. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, et al. Randomized, dose-escalation study of the p38alphaMAPKinhibitor SCIO- 469 in patients with myelodysplastic syndrome. Leukemia 2013;27: 977-80.
9. Siegel DS, Krishnan A, Lonial S, Chatta G, Alsina M, Jagannath S, et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2006;108:1022a, 3580.
10. Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 2014;13: 364-74.
11. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008;141: 598-606.
12. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008;6:1630-8.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, et al. Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther 2015;98:76-86.
15. Lim MY, Wang H, Kapoun AM,O'Connell M, O'Young G, Brauer HA, et al. p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 2004;37:1111-4.
16. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.